Clinical trial discovery
Find Clinical Trials
Search studies by condition, treatment, location, eligibility, or trial identifier.
Showing 1–11 of 11 trials
Active filters
Clinical trials found
Published and searchable clinical trials
Searching for clinical trials...
NCT01371630
- Conditions
- B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1, B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative, Burkitt Lymphoma, +23 more
- Locations
-
- M D Anderson Cancer Center Houston, Texas, United States
NCT07097363
- Conditions
- B-Cell Non-Hodgkin Lymphoma, Burkitt Lymphoma, DNA Virus Infections, +23 more
- Locations
-
- Fred Hutch/University of Washington Cancer Consortium Seattle, Washington, United States
Recruiting
SynKIR-310 for Relapsed/Refractory B-NHL
NCT06544265
- Conditions
- Aggressive B-Cell Non-Hodgkin Lymphoma, B Cell Lymphoma, Blood Protein Disorders, +54 more
- Locations
-
- Colorado Blood Cancer Institute, part of Sarah Cannon Cancer Institute Denver, Colorado, United States
- Winship Cancer Institute of Emory University Atlanta, Georgia, United States
- The University of Kansas Cancer Center Fairway, Kansas, United States
- Rutgers Cancer Institute New Brunswick, New Jersey, United States
NCT04231877
- Conditions
- ALK-Positive Large B-Cell Lymphoma, Aggressive Non-Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, +17 more
- Locations
-
- Fred Hutch/University of Washington Cancer Consortium Seattle, Washington, United States
NCT03742258
- Conditions
- Diffuse Large B-Cell Lymphoma Activated B-Cell Type, Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type, Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, +15 more
- Locations
-
- Northwestern University Chicago, Illinois, United States
- Northwestern Lake Forest Hospital Lake Forest, Illinois, United States
Active, Not Recruiting
Testing the Addition of a New Anti-cancer Drug, Venetoclax, to Usual Chemotherapy for High Grade B-cell Lymphomas
NCT03984448
- Conditions
- Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Diffuse Large B-cell Lymphoma, Double-Expressor Lymphoma, +16 more
- Locations
-
- University of Alabama at Birmingham Cancer Center Birmingham, Alabama, United States
- Anchorage Associates in Radiation Medicine Anchorage, Alaska, United States
- Anchorage Radiation Therapy Center Anchorage, Alaska, United States
- Alaska Breast Care and Surgery LLC Anchorage, Alaska, United States
Active, Not Recruiting
Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma
NCT04799275
- Conditions
- Ann Arbor Stage III Diffuse Large B-Cell Lymphoma, Ann Arbor Stage IIX (Bulky) Diffuse Large B-Cell Lymphoma, Ann Arbor Stage IV Diffuse Large B-Cell Lymphoma, +30 more
- Locations
-
- Banner University Medical Center - Tucson Tucson, Arizona, United States
- University of Arizona Cancer Center-North Campus Tucson, Arizona, United States
- University of Arkansas for Medical Sciences Little Rock, Arkansas, United States
- Kaiser Permanente-Anaheim Anaheim, California, United States
Active, Not Recruiting
Nivolumab With or Without Varlilumab in Treating Patients With Relapsed or Refractory Aggressive B-cell Lymphomas
NCT03038672
- Conditions
- ALK-Positive Large B-Cell Lymphoma, Burkitt Lymphoma, DNA Virus Infections, +53 more
- Locations
-
- Mayo Clinic Hospital in Arizona Phoenix, Arizona, United States
- Mayo Clinic in Arizona Scottsdale, Arizona, United States
- Mayo Clinic in Florida Jacksonville, Florida, United States
- Moffitt Cancer Center-International Plaza Tampa, Florida, United States
Active, Not Recruiting
Nivolumab With DA-REPOCH Chemotherapy Regimen in Treating Patients With Aggressive B-Cell Non-Hodgkin's Lymphoma
NCT03749018
- Conditions
- Aggressive Non-Hodgkin Lymphoma, Ann Arbor Stage I Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma, Ann Arbor Stage II B-Cell Non-Hodgkin Lymphoma, +22 more
- Locations
-
- Ohio State University Comprehensive Cancer Center Columbus, Ohio, United States
Active, Not Recruiting
Cellular Immunotherapy Following Chemotherapy in Treating Patients With Recurrent Non-Hodgkin Lymphomas, Chronic Lymphocytic Leukemia, or B-Cell Prolymphocytic Leukemia
NCT02153580
- Conditions
- B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classic Hodgkin Lymphoma, B-Cell Prolymphocytic Leukemia, Burkitt Lymphoma, +43 more
- Locations
-
- City of Hope Comprehensive Cancer Center Duarte, California, United States
Active, Not Recruiting
Zanubrutinib and CAR T-cell Therapy for the Treatment of Recurrent or Refractory Aggressive B-cell Non-Hodgkin's Lymphoma or Transformed Indolent B-cell Lymphoma
NCT05202782
- Conditions
- Diffuse Large B-Cell Lymphoma Associated With Chronic Inflammation, EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Hemic and Lymphatic Diseases, +27 more
- Locations
-
- Northwestern University Chicago, Illinois, United States
- Medical College of Wisconsin Milwaukee, Wisconsin, United States